Tg Therapeutics (TGTX) Change in Acquisitions & Divestments (2015 - 2026)

Tg Therapeutics' Change in Acquisitions & Divestments history runs 12 years deep, the most recent figure standing at $11.2 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 86.01% year-over-year to $11.2 million in Q1 2026; TTM through Mar 2026 was $168.4 million, a 47.04% decrease from a year earlier, with the FY2025 full-year figure at $237.5 million, down 23.61% from the prior year.
• Change in Acquisitions & Divestments eased to $11.2 million in Q1 2026 per TGTX's latest filing, from $30.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $92.3 million in Q3 2024 and bottomed at $11.2 million in Q1 2026.
• The 5-year median for Change in Acquisitions & Divestments is $30.0 million (2025), against an average of $43.7 million.
• Across the five-year window, Change in Acquisitions & Divestments surged 358.76% in 2024 and slumped 86.01% in 2026, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $20.3 million in 2022, then grew by 16.81% to $23.7 million in 2023, then surged by 211.26% to $73.7 million in 2024, then slumped by 59.29% to $30.0 million in 2025, then sank by 62.5% to $11.2 million in 2026.
• Per Business Quant, the three latest TGTX Change in Acquisitions & Divestments figures stand at $11.2 million (Q1 2026), $30.0 million (Q4 2025), and $77.8 million (Q3 2025).